NEU 2.81% $18.65 neuren pharmaceuticals limited

Ann: Q4 2021 quarterly activity and cash flow report, page-7

  1. 2,211 Posts.
    lightbulb Created with Sketch. 326
    Very nice QTRLY, progress on ROW, re submitting of NNZ-2591 for multiple neurodevelopmental disorders and • $36.8 million cash at 31 December 2021 – well funded to execute NNZ-2591 trials and
    foundational work for Phase 3 across all indications.

    What's NOT to Like? Yet we get some crazy constant selling of a few shares, pushing down the SP as she starts to run.
    it is very frustrating to watch.

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.